目的：观察逐水通阳救肺方联合诱导化疗治疗Ⅲb/IV 期非小细胞肺癌（NSCLC） 的临床疗效。方法：选取118 例Ⅲb/IV 期NSCLC 患者，按随机数字表法分为对照组及观察组各59 例。对照组给予诱导化疗治疗，观察组在诱导化疗基础上给予逐水通阳救肺方治疗。2 组均治疗3 个周期后评价疗效。比较2 组临床疗效，比较2 组治疗前后免疫功能指标及卡氏（KPS） 评分的变化，观察2 组治疗期间用药安全性［消化道反应、白细胞计数（WBC） 下降、血小板（BPC） 下降、血红蛋白（Hb） 下降、谷丙转氨酶（ALT） 升高］。结果：观察组临床疗效总有效率为27.12%，对照组为20.34%，2 组比较，差异无统计学意义（P＞0.05）。治疗后，2 组CD8+均较治疗前下降，CD3+、CD4+、CD4+/CD8+指标值均较治疗前升高（P＜0.05）；且观察组CD8+低于对照组，CD3+、CD4+、CD4+/CD8+指标值均高于对照组（P＜0.05）。治疗期间，观察组在消化道反应、WBC 下降、BPC 下降、Hb 下降不良反应的发生率均低于对照组（P＜0.05），ALT 升高发生率与对照组比较，差异无统计学意义（P＞0.05）。治疗后，2 组KPS 评分均较治疗前升高（P＜0.05），观察组KPS 评分高于对照组（P＜0.05）。结论：逐水通阳救肺方联合诱导化疗治疗Ⅲb/IV 期NSCLC 可缓解诱导化疗导致免疫功能下降的情况，减轻不良反应，提高患者生活质量。
Abstract： Objective： To observe the clinical effect of the therapy of Zhushui Tongyang Jiufei Prescription combined with induction chemotherapy on stage Ⅲb/Ⅳ non- small cell lung cancer(NSCLC). Methods： A total of 118 patients with stage Ⅲb/Ⅳ NSCLC were divided into the control group and the observation group according to the random number table method，with 59 cases in each group. The control group was treated with induction chemotherapy，and the observation group was additionally treated with Zhushui Tongyang Jiufei Prescription based on induction chemotherapy. The curative effects in the two groups were evaluated after three courses of treatment. The clinical effects were compared between the two groups. Before and after treatment， the changes of indexes of immune function and scores of Karnofsky Performance Score(KPS) were compared between the two groups. During treatment， the administration safety， including gastrointestinal reaction， decrease of white blood cell(WBC)， blood platelet count(BPC)， hemoglobin(Hb) and increase of alanine aminotransferase(ALT)， in the two groups was observed. Results：The total clinical effective rate was 27.12% in the observation group and 20.34% in the control group，the difference being no significance(P＞0.05). After treatment，the levels of CD8+ in the two groups were decreased when compared with those before treatment，and the levels of CD3+，CD4+ and CD4 +/CD8 + were increased(P＜0.05)； the level of CD8 + in the observation group was lower and the levels of CD3+、CD4+、CD4+/CD8+ in the observation group were higher than those in the control group(P＜ 0.05). During treatment，the incidence of gastrointestinal reaction and decrease of WBS，BPC and Hb and adverse reactions in the observation group were lower than those in the control group(P＜0.05)，and there was no significance being found in the comparison of incidence of increase of ALT between the two groups (P＞0.05). After treatment，the scores of KPS in the two groups were increased when compared with those before treatment(P＜0.05)，and the above score in the observation group was higher than that in the control group(P＜0.05). Conclusion：The therapy of Zhushui Tongyang Jiufei Prescription combined with induction chemotherapy for stage Ⅲb/Ⅳ NSCLC can relieve the decrease of immune function caused by induction chemotherapy，reduce the adverse reactions，and enhance the quality of life of patients.